ERBB2 and breast carcinoma: The model can be expanded to incorporate additional resistance mechanisms relevant to HER2+ breast cancer (e.g. the FGFR signaling pathway in the context of estrogen receptor degraders (Turner et al., 2010; André & Cortés, 2015; Mao et al., 2017)).